What is TreeFrog Therapeutics?
TreeFrog Therapeutics is a French biotechnology company founded in 2018, specializing in the development of cell therapies. The company has engineered C-StemTM, a proprietary technology platform designed for the high-throughput encapsulation and mass-production of stem cells within industrial bioreactors. This innovative approach aims to provide a scalable, end-to-end solution that enhances the quality of therapeutic cells while simultaneously reducing manufacturing costs. TreeFrog Therapeutics is positioned to address critical needs in the accessibility of advanced cell-based treatments for patients.
How much funding has TreeFrog Therapeutics raised?
TreeFrog Therapeutics has raised a total of $114.8M across 3 funding rounds:
Series A
$5.7M
Series B
$75M
Other Financing Round
$34.1M
Series A (2019): $5.7M, investors not publicly disclosed
Series B (2021): $75M led by Leonard Green & Partners, Bpifrance, Bristol-Myers Squibb, and XAnge
Other Financing Round (2025): $34.1M supported by European Investment Bank
Key Investors in TreeFrog Therapeutics
Leonard Green & Partners
Leonard Green & Partners is a prominent private equity firm established in 1989, managing over $50 billion in assets. The firm specializes in investing in market-leading companies, often partnering with management teams and founders across various sectors including services, retail, distribution, and industrials.
Bpifrance
Bpifrance, founded in 2012, is a French public investment bank that provides financing, guarantees, and equity to companies at all stages of development. It supports innovation, international expansion, and export activities, offering a comprehensive suite of services for entrepreneurs.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. Their expertise spans oncology, cardiovascular disease, immunoscience, and virology, with a commitment to research and development and strategic collaborations.
What's next for TreeFrog Therapeutics?
The substantial enterprise-level funding TreeFrog Therapeutics has attracted indicates a strong market validation and positions the company for significant scaling and further research and development. This capital infusion is expected to accelerate the company's efforts to bring its cell therapy solutions to a wider patient population. Future strategic initiatives will likely focus on expanding manufacturing capabilities, advancing clinical trials, and forging key partnerships within the biopharmaceutical industry to solidify its market presence and drive innovation in regenerative medicine.
See full TreeFrog Therapeutics company page
